
Regentis Biomaterials Advances GelrinC Hydrogel Implant Toward Key Commercial Milestones for Knee Cartilage Repair
Regentis Biomaterials' cell-free GelrinC implant, offering a simplified 10-minute procedure, is progressing through pivotal trials and targeting a $3 billion U.S. market with no approved off-the-shelf regenerative solution, potentially disrupting current treatment paradigms.
Read full story


























